Update kardiorenales Syndrom

Zusammenfassung

Das kardiorenale Syndrom bezeichnet die Interaktion zwischen Herz- und Nierenerkrankungen. Akute oder chronische Funktionseinschränkungen des einen Organs können dabei zu akuten oder chronischen Funktionseinschränkungen des jeweils anderen führen. Die Prävalenz nimmt seit Jahren stetig zu. Betroffene Patienten gehören zur kardiovaskulären Hochrisikogruppe, deren adäquate leitliniengerechte Therapie unerlässlich ist. Im Folgenden möchten wir einen Überblick über neueste Studienergebnisse geben und auf wichtige Komorbiditäten und deren Behandlung hinweisen.

Abstract

The cardiorenal syndrome comprises interactions between heart and kidney disorders. This interaction is bidirectional: acute or chronic dysfunction in one organ may induce an acute or chronic dysfunction in the other one. Due to aging population and better survival after acute myocardial infarction, the prevalence of the cardiorenal syndrome is steadily rising. As the cardiorenal syndrome comes along with high morbidity and mortality, adequate guideline-based therapy is essential to improve patientsʼ outcome and their quality of life. In the following, we would like to give an overview about novel clinical trial results concerning the cardiorenal syndrome and important comorbidities.

Was ist wichtig?

• Das kardiorenale Syndrom beschreibt einen Symptomenkomplex als Folgestörung gemeinsam auftretender Herz- und Nierenerkrankungen, die einzeln, aber vor allem in Kombination, mit einer schlechten Prognose assoziiert sind.

• Eine leitliniengerechte Herzinsuffizienztherapie mit konsequenter RAAS-Blockade und individualisierter diuretischer Therapie kann die Prognose und Symptomatik der Patienten verbessern.

• Die Pharmakotherapie kann durch die bestehende Nierenfunktionseinschränkung und das Auftreten von Hyperkaliämien limitiert sein.

• Studien zum Einsatz von neuen Substanzen (SGLT-II-Inhibitoren, Kaliumbinder, ARNI) bei Patienten mit kardiorenalem Syndrom werden dringend benötigt und schließen aktuell zum Teil bereits entsprechende Patienten ein.

Schlüsselwörter

Herzinsuffizienz - Nierenfunktionseinschränkung - kardiorenales Syndrom - evidenzbasierte medikamentöse Therapie

Key words

heart failure - kidney disease - cardiorenal syndrome - guideline-based therapy

• Literatur

• 1 Ronco C, Haapio M, House AA. et al. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527-1539 doi:10.1016/j.jacc.2008.07.051
• 2 Rangaswami J, Bhalla V, Blair JEA. et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. Circulation 2019; 139: e840-e878 doi:10.1161/CIR.0000000000000664
• 3 Schwenger V, Remppis B, Westenfeld R. et al. Dialyse- und Ultrafiltrationsverfahren bei kardio-renalem Syndrom. Empfehlung der Arbeitsgemeinschaft „Herz – Niere“ der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. und der Deutschen Gesellschaft für Nephrologie e.V. Dtsch Med Wochenschr 2014; 139: e1-e8 doi:10.1055/s-0033-1360037
• 4 McMahon LP, Roger SD, Levin A. et al. Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease. J Am Soc Nephrol 2004; 15: 1640-1647 doi:10.1097/01.asn.0000130566.69170.5e
• 5 Paoletti E, Bellino D, Cassottana P. et al. Left Ventricular Hypertrophy in Nondiabetic Predialysis CKD. Am J Kidney Dis 2005; 46: 320-327 doi:10.1053/j.ajkd.2005.04.031
• 6 Faul C, Amaral AP, Oskouei B. et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408 doi:10.1172/JCI46122
• 7 Mullens W, Abrahams Z, Francis GS. et al. Importance of Venous Congestion for Worsening of Renal Function in Advanced Decompensated Heart Failure. J Am Coll Cardiol 2009; 53: 589-596 doi:10.1016/j.jacc.2008.05.068
• 8 Damman K, Navis G, Smilde TDJ. et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 2007; 9: 872-878 doi:10.1016/j.ejheart.2007.05.010
• 9 Patel S, Rauf A, Khan H. et al. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. Biomed Pharmacother 2017; 94: 317-325 doi:10.1016/j.biopha.2017.07.091
• 10 Haase M, Müller C, Damman K. et al. Pathogenesis of Cardiorenal Syndrome Type 1 in Acute Decompensated Heart Failure: Workgroup Statements from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 2013; 182: 99-116 doi:10.1159/000349969
• 11 Inker LA, Schmid CH, Tighiouart H. et al. Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C. N Engl J Med 2012; 367: 20-29 doi:10.1056/NEJMoa1114248
• 12 Bauer L, Emrich IE, Pickering JW. et al. Best Albuminuria Measurement to Predict Cardiovascular and Renal Events. Am J Nephrol 2016; 43: 383-388 doi:10.1159/000446483
• 13 Ahmad T, Jackson K, Rao VS. et al. Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury. Circulation 2018; 137: 2016-2028 doi:10.1161/CIRCULATIONAHA.117.030112
• 14 ter Maaten JM, Dunning AM, Valente MAE. et al. Diuretic response in acute heart failure – an analysis from ASCEND-HF. Am Heart J 2015; 170: 313-321.e4 doi:10.1016/j.ahj.2015.05.003
• 15 Costanzo MR, Negoianu D, Jaski BE. et al. Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure. JACC Heart Fail 2016; 4: 95-105 doi:10.1016/j.jchf.2015.08.005
• 16 Grossekettler L, Schmack B, Meyer K. et al. Peritoneal dialysis as therapeutic option in heart failure patients. ESC Heart Fail 2019; 6: 271-279 doi:10.1002/ehf2.12411
• 17 Ponikowski P, Voors AA, Anker SD. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016; 37: 2129-2200 doi:10.1093/eurheartj/ehw128
• 18 Hiremath S, Fergusson DA, Fergusson N. et al. Renin-Angiotensin System Blockade and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Meta-analysis of Randomized Controlled Trials. Am J Kidney Dis 2017; 69: 78-86 doi:10.1053/j.ajkd.2016.08.018
• 19 Sarwar CMS, Papadimitriou L, Pitt B. et al. Hyperkalemia in Heart Failure. J Am Coll Cardiol 2016; 68: 1575-1589 doi:10.1016/j.jacc.2016.06.060
• 20 Albert NM, Yancy CW, Liang L. et al. Use of aldosterone antagonists in heart failure. JAMA 2009; 302: 1658-1665 doi:10.1001/jama.2009.1493
• 21 Yildirim T, Arici M, Piskinpasa S. et al. Major Barriers against Renin-Angiotensin-Aldosterone System Blocker Use in Chronic Kidney Disease Stages 3-5 in Clinical Practice: A Safety Concern?. Ren Fail 2012; 34: 1095-1099 doi:10.3109/0886022X.2012.717478
• 22 CONSENSUS Trial Study Group. Effects of Enalapril on Mortality in Severe Congestive Heart Failure. N Engl J Med 1987; 316: 1429-1435 doi:10.1056/NEJM198706043162301
• 23 Beldhuis IE, Myhre PL, Claggett B. et al. Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. JACC Heart Fail 2019; 7: 25-32 doi:10.1016/j.jchf.2018.10.017
• 24 Damman K, Gori M, Claggett B. et al. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC Heart Fail 2018; 6: 489-498 doi:10.1016/j.jchf.2018.02.004
• 25 Linde C, Qin L, Bakhai A. et al. Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21334 patients in the UK. ESC Heart Fail 2019; 6: 280-290 doi:10.1002/ehf2.12402
• 26 Krogager ML, Torp-Pedersen C, Mortensen RN. et al. Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data. Eur Heart J 2017; 38: 104-112 doi:10.1093/eurheartj/ehw129
• 27 Savarese G, Xu H, Trevisan M. et al. Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. JACC Heart Fail 2019; 7: 65-76 doi:10.1016/j.jchf.2018.10.003
• 28 Pitt B, Bakris GL, Weir MR. et al. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. ESC Heart Fail 2018; 5: 592-602 doi:10.1002/ehf2.12292
• 29 Pitt B, Bushinsky DA, Kitzman DW. et al. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. ESC Heart Fail 2018; 5: 257-266 doi:10.1002/ehf2.12265
• 30 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128 doi:10.1056/NEJMoa1504720
• 31 Neal B, Perkovic V, Mahaffey KW. et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377: 644-657 doi:10.1056/NEJMoa1611925
• 32 Wiviott SD, Raz I, Bonaca MP. et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380: 347-357 doi:10.1056/NEJMoa1812389
• 33 Wanner C, Heerspink HJL, Zinman B. et al. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. J Am Soc Nephrol 2018; 29: 2755-2769 doi:10.1681/ASN.2018010103
• 34 Perkovic V, Jardine MJ, Neal B. et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380: 2295-2306 doi:10.1056/NEJMoa1811744
• 35 McMurray JJV, Solomon SD, Inzucchi SE. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 19.09.2019;
• 36 Chan KY, Benjamin Cheng HW, Yap DY. et al. Reduction of Acute Hospital Admissions and Improvement in Outpatient Attendance by Intensified Renal Palliative Care Clinic Follow-Up: The Hong Kong Experience. J Pain Symptom Manage 2015; 49: 144-149 doi:10.1016/j.jpainsymman.2014.04.010
• 37 Davison SN, Koncicki H, Brennan F. Pain in Chronic Kidney Disease: A Scoping Review. Semin Dial 2014; 27: 188-204 doi:10.1111/sdi.12196
• 38 Fukuta H, Goto T, Wakami K. et al. Effects of drug and exercise intervention on functional capacity and quality of life in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. Eur J Prev Cardiol 2016; 23: 78-85 doi:10.1177/2047487314564729